Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascrinvacumab in Relapsed/Refractory Urothelial Cancer
NCT01620970Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Mar 2012
- Primary completion
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ascrinvacumab in urothelial carcinoma (UC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Progression-free survival at 2 months. Started Mar 2012; status: completed.
02
Drugs
ascrinvacumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01620970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01620970.